DUAN Wenhu
Principal Investigator
Small-Molecule Drug Research Center
Personal Homepage
CONTACT
whduan@simm.ac.cn
+86-21-50806032
201203
Shanghai Institute of Materia Medica , Chinese Academy of Sciences Address: 555 Zu Chong Zhi Road , Zhang Jiang Hi-Tech Park, Pudong, Shanghai
Biography
Dr. DUAN Wenhu, obtained B.S. degree from China Pharmaceutical University in 1986, M.S. from West-China Medical University in 1993, and Ph.D. from Shanghai Institute of materia Medica in 1996; From 1997 to 2000, did post-doctoral research in Rensselaer Polytechnic Institute and University of Texas. Currently he is professor and PI at Shanghai Institute of Materia Medica. He has published more than 100 research papers and filed more than 30 patents. Research field: Medicinal Chemistry.
EDUCATION
09/1993-06/1996, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
09/1990-06/1993, West China University of Medical Sciences
09/1982-06/1986, China Pharmaceutical University
WORK EXPERIENCE
10/2001-to date, professor and PI, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
09/2000-09/2001, senior scientist, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
04/2000-08/2000, Postdoctoral Research Fellow with Professor Laurence Hurley, The University of Arizona
04/1999-03/1999, Postdoctoral Research Fellow with Professor Laurence Hurley, The University of Texas at Austin
11/1997-03/1999, Postdoctoral Research Fellow with Professor Mark Wentland, Rensselaer Polytechnic Institute
02/1997-08/1999, Postdoctoral Research Fellow with Professor John Falck, The University of Texas Southwestern Medical Center at Dallas
Research Directions
The major research interests include two parts:
1. discovery and development of targeted anticancer agents, we use a combination of structure-based and classical drug designing strategies to identify new anticancer agents with high efficacy and low toxicity by targeting those enzymes/proteins which are crucial to growth, survival, differentiation, and angiogenesis in cancers. We are mainly focused on tyrosine kinases, e.g., c-Met, KDR, FGFR, and etc;
2. synthesis and structural modification of natural products with antitumor activities to identify anticancer agents with unique mechanism of action.
Grants & Research Projects
1. National Science Foundation of China, Design, synthesis of new c-Met inhibitors as antitumor agents (81273365)
2. National Science Foundation of China, Design, synthesis of selective VEGFR-2 inhibitors as antitumor agents (15431901300)
3. National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program, Identification and preclinical studies of Androgen Receptpr Antagonis (2014ZX09304002-008)
4. The Project of Ministry of Major Science & Technology of Shanghai, Preclinical studies of selective VEGFR-2 inhibitor (15431901300)
5. The Project of Ministry of Major Science & Technology of Shanghai, Preclinical studies of Triazolotriazines as C-Met inhibitor (11431921101)
6. Strategic Priority Research Program of the Chinese Academy of Sciences, Discovery and biological studies of potent Pan-FGFR1-4 inhibitors (XDA12020303)
Achievements
morefold
Social Titles
morefold
Awards & Honors
12/2007, First award of Shanghai Municipal Science and Technology
morefold
Pubilcations
Full Publication List
Selected Publications
1. Jingwei Shao, Kongkai Zhu, Daohai Du, Yuanyuan Zhang, Hongrui Tao, Zhifeng Chen, Hualiang Jiang, Kaixian Chen, Cheng Luo*, Wenhu Duan*. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2019, 164(15):317-333.
2. Kongkai Zhu, Jingwei Shao, Hongrui Tao, Xue Yan, Cheng Luo, Hua Zhang*, Wenhu Duan*. Rational design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. Journal of Computer-Aided Molecular Design, 2019, 33(8): 775-785.
3. Yuming Wang, Lijun Li, Jun Fan, Yang Dai, Alan Jiang, Meiyu Geng, Jing Ai*, and Wenhu Duan*. Discovery of potent irreversible pan-fibroblast growth factor receptor (FGFR) inhibitors. Journal of Medicinal Chemistry, 2018, 61(20): 9085-9104.
4. Zhengsheng Zhan, Xia Peng, Yiming Sun, Jing Ai*, and Wenhu Duan*. Evaluation of deuterium-labeled JNJ38877605: pharmacokinetic, metabolic, and in vivo antitumor profiles. Chemical Research in Toxicology, 2018, 31(11): 1213-1218.
5. Ruifeng Mao, Jingwei Shao, Kongkai Zhu, Yuanyuan Zhang, Hong Ding, Chenhua Zhang, Zhe Shi, Hualiang Jiang, Dequn Sun*, Wenhu Duan*, and Cheng Luo*. Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization. Journal of Medicinal Chemistry, 2017, 60(14): 6289-6304.
6. Zhengyu Wang, Xiaofan Shi, Huan Zhang, Liang Yu, Yanhua Cheng, Hefeng Zhang, Huibin Zhang, Jinpei Zhou*, Jing Chen*, Xu Shen, and Wenhu Duan*. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2017, 139: 128-152.
7. Wei Yan, Xinyi Wang, Yang Dai, Bin Zhao, Xinying Yang, Jun Fan, Yinglei Gao, Fanwang Meng, Yuming Wang, Chen Luo, Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Discovery of 3-(5'-substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation. Journal of Medicinal Chemistry, 2016, 59(14): 6690-6708.
8. Bin Zhao, Yixuan Li, Pan Xu, Yang Dai, Cheng Luo, Yiming Sun, Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Discovery of substituted 1H-pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors. ACS Medicinal Chemistry Letters, 2016, 7(6): 629-634.
9. Jun Fan, Yang Dai, Jingwei Shao, Xia Peng, Chen Wang, Sufen Cao, Bin Zhao,Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Bioorganic & Medicinal Chemistry Letters, 2016, 26 (11): 2594-2599.
10. Zhengsheng Zhan, Xia Peng, Qiufeng Liu, Fang Chen, Yinchun Ji, Shanyan Yao, Yong Xi, Yipeng Lin, Tiantian Chen, Yechun Xu*, Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b] [1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. European Journal of Medicinal Chemistry, 2016, 116: 239-251.
11. Wei Yan, Zhaoru Huang, Zhengyu Wang, Sufen Cao, Linjiang Tong, Tao Zhang, Chen Wang, Lin Zhou, Jian Ding, Cheng Luo*, Jinpei Zhou*, Hua Xie*, and Wenhu Duan*. Discovery of 1,3-diaryl-pyridones as potent VEGFR-2 inhibitors: design, synthesis, and biological evaluation. Chemical Biology & Drug Design, 2016, 87(5): 694-703.
12. Mengyuan Li, Yongcong Lv, Linjiang Tong, Ting Peng, Rong Qu, Tao Zhang, Yiming Sun, Yi Chen, Lixin Wei, Meiyu Geng, Wenhu Duan*, Hua Xie*, and Jian Ding*. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacologica Sinica, 2016, 37 (3): 398-407.
13. Guorui Gao, Mengyuan Li, Yongcong Lv, Sufen Cao, Linjiang Tong, Lixin Wei, Jian Ding, Hua Xie, and Wenhu Duan*. Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II). Chinese Chemical Letters, 2016, 27(2): 200-204.
14. Guorui Gao, Mengyuan Li, Linjiang Tong, Lixin Wei, Jian Ding*, Hua Xie*, and Wenhu Duan*. Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I). Chinese Chemical Letters, 2015, 26(9): 1165-1168.
15. Yongcong Lv, Mengyuan Li, Sufen Cao, Linjiang Tong, Ting Peng, Lixin Wei, Hua Xie*, Jian Ding*, and Wenhu Duan*. Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors. MedChemComm, 2015, 6(7): 1375-1380.
16. Yanyan Sun, Jun Fan, Zhiyuan Zhu*, Xiaodan Guo, Tingting Zhou, Wenhu Duan*, and Xu Shen*. Small molecule TBTC as a new selective retinoid X receptor α agonist improves behavioral deficit in alzheimer's disease model mice. European Journal of Pharmacology, 2015, 762: 202-213.
17. Jianrui Wu, Ting Peng, Fang Chen, Yixin Leng , Linjiang Tong, Mengyuan Li, Rong Qu , Hua Xie*, Jian Ding*, and Wenhu Duan*. Synthesis and anticancer activity of 7,8-dihydroxy-4-arylcoumarins. Letters in Drug Design & Discovery, 2015, 12(5): 366-73.
18. Guorui Gao, Jiali Liu, Desheng Mei, Jian Ding, Linghua Meng*, and Wenhu Duan*. Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors. Chinese Chemical Letters, 2015, 26 (1): 118-120.
19. Ting Peng, Jianrui Wu, Linjiang Tong, Mengyuan Li, Fang Chen, Yixin Leng, Rong Qu, Kun Han, Yi Su, Yi Chen, Wenhu Duan*, Hua Xie*, and Jian Ding*. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin. Acta Pharmacologica Sinica, 2014, 35(7): 916-928.
20. Zhengsheng Zhan, Jing Ai, Qiufeng Liu, Yinchun Ji, Tiantian Chen, Yechun Xu*, Meiyu Geng*, and Wenhu Duan*. Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: synthesis, SAR, and cellular activity. ACS Medicinal Chemistry Letters, 2014, 5(6): 673-678.
21. Yongcong Lv, Mengyuan Li, Ting Liu, Linjiang Tong, Ting Peng, Lixin Wei, Jian Ding, Hua Xie*, and Wenhu Duan*. Discoverr of a new series of naphthamides as potent VEGFR-2 kinase inhibitors. ACS Medicinal Chemistry Letters, 2014, 5(5): 592-597.
morefold
Back